Welcome to our dedicated page for Annovis Bio SEC filings (Ticker: ANVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking buntanetap’s clinical progress is critical, yet Annovis Bio SEC filings bury key data beneath pages of molecular biology and accounting notes. Locating cash-runway figures, patent expirations, or new trial endpoints inside an annual report can feel like decoding lab notebooks.
Stock Titan solves the problem. Our AI-powered engine converts every Annovis Bio annual report 10-K simplified into readable language, highlights R&D spending trends, and calls out FDA correspondence in seconds. Real-time alerts flag Annovis Bio Form 4 insider transactions real-time, so you never miss executive stock moves. Need fast numbers? We pair each Annovis Bio quarterly earnings report 10-Q filing with visual trend lines and ratio analysis, while Annovis Bio 8-K material events explained arrive minutes after EDGAR posts.
- Form 4: Monitor Annovis Bio insider trading Form 4 transactions and option grants for fresh sentiment cues.
- 10-K & 10-Q: Review pipeline milestones, licensing revenue, and burn-rate assumptions—understanding Annovis Bio SEC documents with AI makes it simple.
- 8-K: Catch trial-readout surprises, financing deals, and leadership changes as they happen.
- DEF 14A: Dive into the Annovis Bio proxy statement executive compensation without parsing legalese.
Whether you’re comparing phase-2 efficacy data, evaluating future dilution risk, or seeking Annovis Bio earnings report filing analysis, our platform provides comprehensive coverage of ALL forms, updated in real time. Stay ahead with AI summaries that clarify complex science and finance, and make smarter decisions backed by complete, accessible information.
Annovis Bio, Inc. (NYSE: ANVS) filed a Form 8-K reporting the outcome of its 2025 virtual Annual Meeting held on 17 June 2025.
Quorum: 11,588,981 shares (59.47% of shares outstanding).
Proposal 1 – Election of Directors (one-year terms):
- Maria Maccecchini – 4,216,112 FOR / 173,438 WITHHELD / 7,199,431 broker non-votes
- Michael Hoffman – 4,182,806 FOR / 206,744 WITHHELD / 7,199,431 broker non-votes
- Claudine Bruck – 4,041,007 FOR / 348,543 WITHHELD / 7,199,431 broker non-votes
- Reid McCarthy – 4,202,391 FOR / 187,159 WITHHELD / 7,199,431 broker non-votes
- Mark White – 3,780,238 FOR / 609,312 WITHHELD / 7,199,431 broker non-votes
Proposal 2 – Ratification of Independent Auditor: Ernst & Young LLP ratified with 11,382,542 FOR, 187,959 AGAINST, 18,480 ABSTAIN.
All proposals passed; no additional matters were presented.
Annovis Bio, Inc. (NYSE: ANVS) filed an 8-K on June 19, 2025 to disclose that the New York Stock Exchange has accepted the company’s previously submitted listing-compliance plan. The plan was required after Annovis fell out of compliance with NYSE continued-listing standards; acceptance removes the immediate risk of delisting and starts a defined remediation timetable. The 8-K furnishes, but does not file, a press release (Exhibit 99.1) announcing the NYSE decision. No financial statements, earnings data or major transactions were included, and the disclosure is made solely under Item 7.01 (Regulation FD) with no impact on historical financial reporting.
Investors should note that, while acceptance is a constructive step, Annovis must still meet the milestones outlined in the compliance plan to regain full compliance. The filing contains no new operational or financial metrics.
Annovis Bio (ANVS) Vice President of Finance Andrew Walsh reported a new acquisition of company shares on Form 4. The transaction details include:
- Acquired 500 shares of Common Stock
- Purchase price: $2.90 per share
- Transaction date: June 16, 2025
- Total transaction value: $1,450
- Ownership type: Direct
Following this transaction, Walsh holds 500 shares directly. The purchase represents an initial position for the executive, as no prior holdings were reported. The transaction was reported within the required two-business-day filing window, with the Form 4 being filed on June 28, 2025. No derivative securities were involved in this transaction.
FAQ
What is the current stock price of Annovis Bio (ANVS)?
What is the market cap of Annovis Bio (ANVS)?
What is the core focus of Annovis Bio Inc?
What is buntanetap and how does it work?
What therapeutic areas does Annovis Bio target?
How does the company approach combination therapies?
What makes Annovis Bio’s approach unique in the field of neurodegeneration?
How are the clinical trials designed for the company's candidates?
What is the significance of the company's intellectual property portfolio?
How does Annovis Bio ensure the safety and efficacy of its drug candidates?
